DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% (dopamine hydrochloride) by B. Braun is clinical pharmacology dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (dopa). Approved for hemodynamic status in patients in shock. First approved in 1986.
Drug data last refreshed 16h ago · AI intelligence enriched 5d ago
Dopamine hydrochloride 5% in dextrose is an intravenous catecholamine agonist approved in 1986 for managing hemodynamic instability in shock patients. It works through dose-dependent activation of dopamine, beta-1, and alpha-1 adrenergic receptors to increase cardiac contractility, heart rate, and blood pressure while promoting renal vasodilation at lower doses.
Product approaching loss of exclusivity with high generic/branded competitor pressure; career roles likely focus on managed care negotiation and ICU physician relationships rather than growth initiatives.
CLINICAL PHARMACOLOGY Dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal…
Worked on DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% at B. Braun? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moThis product offers limited career growth due to mature, commodity-like status and approaching loss of exclusivity with minimal differentiation from competitors. Roles are tactical and focused on defending hospital formulary position, managing pricing pressure, and ensuring supply continuity rather than strategic innovation or market expansion.